AKT1 and cancer: Furthermore, we demonstrate that SLC-0111 is able to potentiate Cis-Pt effect on altered signaling pathways involved in cancer progression such as STAT-3, AKT and ERK decreasing the expression levels of the phosphorylated/activated forms of these proteins.